title: [When is it possible to discontinue therapy in pemphigus vulgaris?].
abstract: Discontinuation of therapy in pemphigus vulgaris is risky, even after long remission under therapy. In active pemphigus vulgaris, levamisole suppresses the formation of T-cell-rosettes. The change from suppression to stimulation under the influence of levamisole, parallel to the disappearance of pemphigus antibodies seems to indicate that the therapy may be discontinued with all due caution.
mesh_terms: D000368:Aged; D003907:Dexamethasone / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007978:Levamisole; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D010392:Pemphigus / Q000188:drug therapy* / Q000276:immunology; D011239:Prednisolone / Q000627:therapeutic use; D012397:Rosette Formation; D013601:T-Lymphocytes / Q000187:drug effects
chemical_list: D005938:Glucocorticoids; D007978:Levamisole; D003907:Dexamethasone; D011239:Prednisolone
vernacular_title: Wann ist es möglich, die Therapie beim Pemphigus vulgaris abzusetzen?